US Executive Compensation Proxy SEC Filings — July 14, 2026

All three director nominees are independent, signaling strong board oversight and alignment with shareholder interests

Single director election with unanimous board recommendation reflects stable governance and no activist pressure

Authorized shares proposed to increase 400% from 25M to 100M, while current float is only 4.7M shares—potential dilution of over 20x if fully utilized

Investor warrants exercised at $1.60/share (44% discount to original $2.86 strike) in June 2025 inducement transaction, signaling desperate capital raising

Outstanding warrants and options cover 10.6M shares vs 4.7M shares outstanding—a 224% overhang that will pressure stock price

Virtual-only annual meeting format (Aug 25, 2026) reduces shareholder engagement costs but may limit retail investor participation

Quorum requirement of only one-third of votes is low, potentially allowing small shareholder groups to control outcomes

No commitments for future share issuance despite seeking authorization for 100M shares—creates uncertainty and potential for further dilution

Deloitte & Touche LLP as auditor for FY ending March 31, 2027 provides audit quality consistency

Lars Leckie's venture capital and technology experience brings valuable strategic oversight for a tech company

Proposed increase in authorized shares from 25M to 100M (400% increase) with only 4.7M shares outstanding—potential for massive shareholder dilution

5.58M investor warrants at $1.60/share plus existing 10.6M total warrants/options create 224% overhang vs current float, likely capping stock price appreciation

The authorized share increase could be used as a poison pill to dilute any potential acquirer, entrenching management

No forward-looking statements about revenue or profitability, only capital raising flexibility—suggests ongoing cash burn without clear path to profitability

No insider buying disclosed despite massive dilution proposal—insiders not putting own capital at risk signals lack of confidence

One-third quorum requirement could allow a small minority to elect directors without majority participation

Virtual-only format may reduce shareholder ability to ask questions or engage with board compared to hybrid meetings

No mention of FDA approvals or clinical trial progress—biotech without clear regulatory catalyst is pure speculation

Massive dilution proposal and 224% warrant overhang create a compelling short thesis—stock likely to decline as dilution becomes reality

Shareholders could vote against both proposals to force management to seek less dilutive financing, potentially unlocking value

Routine governance with independent directors and consistent auditor provides safe haven in volatile markets—ideal for risk-averse investors

Lars Leckie's VC background could drive strategic M&A or partnerships—monitor for deal announcements post-meeting

If warrants are exercised at $1.60, current stock price above that level could see selling pressure—options strategies may profit from volatility

No dividend data in filing, but stable governance suggests potential for future capital returns if cash flow improves

Single director election with VC expertise may signal upcoming capital raise or strategic pivot—watch for post-meeting announcements

If proposals pass and stock drops, long-term investors could accumulate at distressed levels if company has viable pipeline

Established companies (GRAHAM, Powerlaw) maintain routine governance with minimal shareholder proposals, while micro-caps (CELZ) pursue aggressive capital structure changes that threaten shareholder value—investors must differentiate between stable and risky governance

The CELZ filing exemplifies how micro-cap biotechs use authorized share increases and warrant inducements to raise capital, often at the expense of existing shareholders—a pattern to watch across the sector

Both GRAHAM and Powerlaw use virtual-only meetings, continuing the post-COVID trend that reduces costs but may limit shareholder engagement—institutional investors increasingly pushing for hybrid options

The absence of insider buying in CELZ's filing despite massive dilution contrasts with the stable governance in GRAHAM and Powerlaw—insider behavior is a key differentiator between value creation and destruction

GRAHAM and Powerlaw focus on routine governance (director elections, auditor ratification), while CELZ prioritizes capital structure flexibility—indicating different stages of corporate lifecycle (mature vs growth/cash-burn)

Vote on dilution proposals—if passed, expect significant stock price decline; if failed, management may seek alternative financing. Date not specified but likely within 60 days of filing

August 25, 2026—watch for any shareholder proposals or dissident votes that could signal governance concerns

August 13, 2026—monitor for any last-minute proxy contests or shareholder dissent

Watch for insider selling post-meeting—if insiders sell after dilution passes, it confirms lack of confidence

Monitor for price decline as dilution risk is priced in—potential entry point for distressed investors if fundamentals support

FY ending March 31, 2027—watch for operational performance that could justify executive compensation levels

Lars Leckie's appointment may lead to strategic changes—monitor for M&A, partnerships, or capital raises

Watch for any 8-K filings about financing agreements or clinical trial updates that could provide context for the dilution need